Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)

K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo, Japan), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), T. Maher (London, United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), V. Kohlbrenner (Ridgefield, Connecticut , United States of America), E. Clerisme-Beaty (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein, Germany), O. Distler (Zurich, Switzerland)

Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Session: Assessment and management of immune-mediated interstitial lung diseases
Session type: Thematic Poster
Number: 4731
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo, Japan), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), T. Maher (London, United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), V. Kohlbrenner (Ridgefield, Connecticut , United States of America), E. Clerisme-Beaty (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein, Germany), O. Distler (Zurich, Switzerland). Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD). 4731

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: